Arcturus Q1 2024 revenue $38M, net loss $26.8M; Kostaive on track for Q3 launch, cash runway through FY2027

Arcturus Therapeutics Holdings Inc.

2024-Q1 EPS reported -$1.00 revenue$38,012,000

Q1 2024 revenue $38.0M (down 53% YoY); net loss $26.8M ($1.00/share) vs net income $50.8M ($1.87) in Q1 2023.
Cash $345.3M; runway extends at least three years to Q1 FY2027; expects future CSL milestones.
Kostaive commercialization on track: initial 4M doses delivery in Q3; European MAA decision expected Q3.
Phase 3 pivotal study for ARCT-2303 (XBB.1.5) initiated; ARCT-2138 flu Phase 1 topline data expected Q3.
ARCT-810 (OTC) and ARCT-032 (CF) data updates on July 1, 2024; JP Morgan engaged to monetize ARCALIS JV stake.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcturus Therapeutics Holdings Inc. reported the three months ended March 31, 2024 results: revenue $38.0 million.

Period: the three months ended March 31, 2024
Revenue: $38.0 million
Result: reported results

Exact text from the filing

For the three months ended March 31, 2024, revenues were $38.0 million compared with $80.3 million for the three months ended March 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-24-000614

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.